en.Wedoany.com Reported - Harbour BioMed (HKEx: 02142) announced the appointment of Dr. Dhavalkumar Patel as a scientific advisor to strengthen the company's research and development strategic layout in the field of immunology.
Dr. Patel currently serves as Executive Vice President and Chief Scientific Officer at Sana Biotechnology, bringing over two decades of therapeutic innovation experience in both industry and academia. Before joining Sana Biotechnology in 2024, he was Executive Vice President and Chief Scientific Officer at UCB, where he advanced the registrations of bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®), and zilucoplan (Zilbrysq®). Earlier, he spent 10 years at Novartis, ultimately serving as Head of European Research at the Novartis Institutes for BioMedical Research (NIBR), leading research in autoimmune, transplant, and inflammatory diseases, contributing to the registrations of secukinumab (Cosentyx®), fingolimod (Gilenya®), siponimod (Mayzent®), canakinumab (Ilaris®), everolimus (Zortress®/Certican®, Afinitor®), leniolisib (Joenja®), and iptacopan (Fabhalta®). He also served as an Entrepreneur in Residence at the Novartis Venture Fund. Dr. Patel was a board member of Inflazome prior to its acquisition by Roche in 2020, and currently serves on the boards of Priothera, Quell Therapeutics, and RE-AIM Therapeutics, as well as Chairman of the Board of Mimetas BV.
Before entering the industry, Dr. Patel was a Distinguished Professor of Medicine, Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill. He also spent nine years at Duke University School of Medicine, ultimately serving as Chief of the Division of Allergy and Immunology. Dr. Patel earned his Bachelor's degree in Microbiology and Immunology, as well as his M.D. and Ph.D. from Duke University, and is board certified in Internal Medicine, Rheumatology, and Allergy and Immunology.
Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, stated that Dr. Patel's deep scientific background in immunology, successful drug development experience, and board-level strategic insights will bring significant value to the company. Dr. Patel expressed that Harbour BioMed has built a portfolio of antibody drug candidates targeting key immune pathways and looks forward to working closely with the team to advance project development.
Harbour BioMed is a global biopharmaceutical company focused on the discovery and development of novel antibody therapies in immunology, oncology, and other disease areas. Its proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies, including both traditional H2L2 formats and heavy-chain-only (HCAb) formats. Based on HCAb, the company has developed the HBICE® bispecific antibody technology and HCAb PLUSTM technology, and launched the first fully human generative AI HCAb model driven by the Hu-mAtrIxTM AI platform.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
